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Abstract 
RRD – photoreceptors detachment from retinal pigment epithelial by retrovitreal fluid, 
which penetrates through the breakdown of the neurosensory part.  
Purpose: investigation of endothelial dysfunction in rhegmatogenous retinal 
detachment pathogenesis and analysis of correction methods effectiveness. 
Von Willebrand factor (VWF) is common marker of endothelial dysfunction.  It was 
established increase in its level in the 7th day of the research  in all groups in which rats were 
modeled rhegmatogenous retinal detachment. Differences in the comparison of these groups 
among themselves have not been identified. 
At 14th day, it is observed endothelial dysfunction development in group 2 
(differences in comparison with the data of intact animals already at the level of significance p 
<0.01). In  group of rats receiving a two-component correction, decrease in the level of VWF 
was found. In the group receiving the three-component correction, the level of the von 
Willebrand factor is more strongly approximated to the norm (p <0.05 when comparing the 
data of this group and the animals that did not undergo correction of the experimental RRD) 
On 21st day no differences were found when comparing the results of intact animals 
with the data of each group receiving  correction of the modeled RRD, indicating the 
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normalization of endothelial cells functioning. It is worth noting that in the group in which 
animals received cytokoline, D-asparagine and L-arginine (group №4),  most expressed 
normalized functional state of the endothelium, as evidenced by the differences in comparison 
with the data of 2nd and 3rd groups on levels of significance p <0.01 
Key words: experimental rhegmatogenous retinal detachment, endothelium 
dysfunction, correction, citokoline, D-asparagine, L-arginine. 
 
Introduction 
RRD – photoreceptors detachment from retinal pigment epithelial by retrovitreal fluid, 
which penetrates through the breakdown of the neurosensory part.  
Unfortunately, surgical intervention at rhegmatogenous retinal detachment  in many 
cases doesn't update functional eye indicators results, which may remain low. Retina 
adherence, achieved surgically, in most patients leads only to  partial restoration of functional 
and structural retina elements, with least restored cone apparatus, which is confirmed by 
electroretinography data [1].  
Incidence of RRD increases with age and reaches 0.06% of the population over the 
age of 60 [2, 3]. Frequency of RRD development  in untreated retinal gaps is 48-55% and 
when  laser-blocked retinal gaps are reduced to 1.84-7.8% [4].  
However, according to Folk J.C. et al [5] prophylactic surgical treatment correction 
does not reduce the likelihood of the rhegmatogenous retinal detachment  development.   
Ratio violation against the backdrop of retinal detachment, macular area and 
photoreceptor layers are most likely  suffer from oxygen lack  and metabolic substrates in 
comparison with its internal layers, although they also undergo significant degenerative 
changes.  Taking into account the above, it is necessary to analyze the vessel endothelium 
dysfunction for better  understanding of the pathogenetic parts of the retinal detachment, as 
well as for the competent selection of  RRD correction methods.  
Purpose: investigation of endothelial dysfunction in rhegmatogenous retinal 
detachment pathogenesis and analysis of correction methods effectiveness.  
Materials and methods.  
In the study were used 120 white rats of the Wistar line. According to the tasks the 
animals were divided into 5 groups: 
1st group – 20 intact animals; 
2nd group – 36 animals, in which rhegmatogenous retinal detachment was modeled; 
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3rd group – 36 animals that received cytokoline and 0.1% of D-asparagine on the 
background of simulated retinal detachment. 
4th group – 36 animals, received cytokoline and D-asparagine in combination with L-
arginine 7% solution administration against background of simulated retinal detachment. 
Rhegmatogenous retinal detachment was modeled using the introduction of 3.5 μl of 
sodium hyaluronate into the subretinal space. Administration was carried out using a self-
sealing scleral incision (after the cut of the conjugate) using a needle 30 G, with further 
formation of a scleral tunnel for sclera and choroid penetration  and a corneal puncture to 
reduce intraocular pressure. Sodium hyaluronate administration into subretinal space was 
performed with 33 G needle, connected with Hamilton syringe of 10 μl, to detach  
neurosensory retina from the underlying RPE (retinal pigment epithelium) (Matsumoto H., 
Miller J. W., Vavvas D. G., 2013 in combination with mechanical injury to the frontal part of 
the head (modeled traumatic brain injury (TBI) using Shubin's O.S. and Egorova MV method, 
1999, reducing in twice standard weight (importance) of  traumatic factor and the height of 
the fall. It was chosen weight 25 g and the height of its incidence of 50 cm, which provides 
less pronounced pathological changes in mild traumatic brain injury). 
At the 7th, 14th, and 21st days of the experiment were taken out 12 rats of each group 
in which rhegmatogenous retinal detachment was modeled. 
It was conducted blood samples from retroorbital venous plexus, which lies in the 
orbit behind eyeball under light, ethereal anesthesia. Puncture is carried out by glass pipette 
circular movements with a drawn capillary, whose tip is stuck at an angle of 45°. Conjunctival 
sac was punctured in the medial angle of the eye between eyeball and orbit. After puncture, 
pipette was injected to 2-4 mm depth for eyeball. Control of penetration into the venous 
plexus was the filling of the capillary pipettes with blood (Dyakonov AV, Khrikina IS, Hegay 
AA, et al., 2013). 
Dosage: Cytokoline - 81.8 mg/kg (0.33 ml/kg) intramuscularly for 14 days and once a 
day. D-asparagine - 0.1% solution. L-arginine - 7% solution. Solutions of D-asparagine and 
L-arginine were dissolved in 100 ml of water and given in a free drinking mode. Cytokoline, 
D-asparagine and L-arginine were administered from 7 day to 21 day from the beginning of 
the study.  
Level of von Willebrand factor was determined by enzyme-linked immunosorbent 
assay. 
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Research results 
Von Willebrand factor (VWF) is common marker of endothelial dysfunction. It was 
established increase in its level in the 7th day of the research  in all groups in which rats were 
modeled rhegmatogenous retinal detachment (Table 1). Differences in the comparison of 
these groups among themselves have not been identified. 
 
Table 1. Dynamics of von Willebrand factor level in rats blood at experimental 
rhegmatogenous retinal detachment   and its correction at the 7th day of the research. 
 
Intact  
animals  
1 
7th day 
Group №2 
2 
Group №3 
3 
Group №4 
4 
VWF 
84.2±1.1 
89.2±1.2 
p21* 
89.1±1.0 
p31* 
89.1±1.3 
p41* 
Footnote: *  – р<0,05 
 
At 14th day, it is observed endothelial dysfunction development in group 2 
(differences in comparison with the data of intact animals already at the level of significance p 
<0.01). In group of rats receiving a two-component correction,  decrease in the level of VWF 
was found. In the group receiving the three-component correction, the level of the von 
Willebrand factor is more strongly approximated to the norm (p <0.05 when comparing the 
data of this group and the animals that did not undergo correction of the experimental RRD) 
(Table 2). 
 
Table 2. Dynamics of von Willebrand factor level in rats blood at experimental 
rhegmatogenous retinal detachment and its correction at the 14th day of the research. 
 
Intact  
animals  
 1 
14th day 
Group №2 
5 
Group №3 
6 
Group №4 
7 
VWF 
84.2±1.1 
90.9±0.9 
p51** 
87.21±1.4 
p61* 
86.0±1.2 
p71* 
p75* 
Footnote: * – р<0,05 
 
On 21st day no differences were found when comparing the results of intact animals 
with the data of each group receiving correction of the modeled RRD, indicating the 
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normalization of endothelial cells functioning. It is worth noting that in the group in which 
animals received cytokoline, D-asparagine and L-arginine (group №4), most expressed 
normalized functional state of the endothelium, as evidenced by the differences in comparison 
with the data of 2nd and 3rd groups on levels of significance p <0.01 (Table 3). 
 
Table 3. Dynamics of von Willebrand factor level in rats blood at experimental 
rhegmatogenous retinal detachment and its correction at the 21st day of the research. 
 
Intact  
animals  
 1 
21st day 
Group №2 
8 
Group №3 
9 
Group №4 
10 
VWF 
84.2±1.1 
91.2±1.2 
p81** 
86.3±0.7 
p98* 
85.4±0.5 
p10-8** 
Footnote: *  – р<0,05 
 
On fig. 1 is given full description of changes in the level of endothelial dysfunction 
marker during the whole experiment. It is clearly confirmed by its progression in animals that 
did not receive correction against the background of the simulated pathology. Most 
pronounced normalization of endothelial cells functioning was found in the group, which 
received a nitric oxide donor as a part of the complex correction (Group № 4)  
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Figure 1. Change  von Willebrand factor level in the blood of experimental animals in 
the dynamics after the experimental rhegmatogenous retinal detachment and its correction  
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Research result discussion  
It is known that under inflammatory mediators influence, endothelial cells lose their 
anti-adhesive and anti-inflammatory properties, forming a prothrombogenic surface that 
stimulates  inflammation development [6]. According to the literature, a correlation between 
the increase of the von Willebrand factor concentration in the blood and the degree of 
endothelial dysfunction, as in the experiment [7], and in a number of clinical observations [8] 
has been proved. In analyzing the factor Willebrand level  in our research, it is confirmed that 
the rhegmatogenous retinal detachment leads to endothelial dysfunction development: 
increase in values of investigated indicator in the background of the simulated pathology has 
been revealed. So in the second group on the 7th day the level of VWF increased by 5.9%, by 
the 14th - by 8%, and by the 21st day - by 8.3%. 
On the background of correction in both groups, a decrease in von Villebrand factor 
level was found. In the third group at day 14, its activity improved by 4.1%, and by the 21st at 
5.4% compared with the data of group №2. And in the fourth group, in comparison with the 
second, its level decreased by 5.4% on the 14th day and by 6.4% on the 21st. Noteworthy fact 
that in group receiving cytokoline, D-asparagine and L-arginine results are better than in the 
group receiving only cytokoline and D-asparagine. Foregoing proves the expediency and 
effectiveness of L-arginine inclusion in the composition of corrective agents in the 
rhegmatogenous retinal detachment.  
Let's take closer look at the L-arginine properties  and the mechanisms of its influence 
on functional state of the endothelial cells. 
Violation of nitric oxide synthesis can lead to endothelial dysfunction (ED), which in 
turn plays important role as regulator of biological effects [9]. In vascular homeostasis, NO is 
responsible for vascular tone, apoptosis and regulation, correction of oxidative processes and 
angioprotective properties. Nitric oxide is also a classic peripheral vasodilator [10]. It is 
generally known that arginine is the main substrate for NO synthesis [11]. This amino acid is 
very important for many metabolism reactions, but its main role is to synthesize nitrogen 
oxide [12]. Therefore, it is required L-arginine for prevention and correction of endothelial 
dysfunction and improvement of blood supply, [13, 14]. Its protector actions are explained as 
follows: it is a precursor of gamma-Aminobutyric acid, L-citrulline, L-ornithine, spermitin,  
L-glutathione  and other compounds [15, 16]. For the first time, this amino acid was isolated 
by E. Schulze and E. Steiger in 1886, and the structure was finally identified by E. Schulze 
and E. Winterstein in 1897. It consists of a positively charged Rh group, which is also an 
integral part of the body's main proteins [17]. L-arginine in the body is converted into two 
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alternative pathways, which can take place simultaneously: with the participation of NO-
synthase - oxidative, with the subsequent formation of L-citrulline and NO; and with the 
participation of arginase I - non-oxide, with subsequent formation of L-ornithine and urea [13, 
14, 18]. 
L-arginine takes  active part in the synthesis of nitric oxide, polyamines and a number 
of anabolic hormones [16]. This amino acid is absorbed by the body in the small intestine and 
then transported to liver, which is mostly utilized in the ornithine cycle, and the other part 
becomes a substrate for the synthesis of NO [19]. In a small amount of L-arginine, which is in 
the plasma, selectively improves the vessels endothelial function, at medium concentrations, 
causes pronounced vasodilatation due to stimulation of insulin secretion and growth hormone, 
while high levels of L-arginine contribute to nonspecific vasodilatation [10, 13, 19, 20]. 
L-arginine activates nitric oxide synthesis  and reduces endothelial dysfunction  
manifestations by increasing endothelial nitric oxide synthase (eNO-S) activity [21]. It also 
prevents tetrahydrobiopterin oxidation  - major co-factor NO-S. By inhibiting the oxidation of 
low density lipoproteins (LDL), which lowers NO, indicated amino acid breaks the eNO-S 
complex with caveolins (potentiated by oxidized LDL), which is an inhibitor of NO-S activity 
[14, 20, 22]. 
L-arginine activates NO action by direct antioxidant activity, increase its bio activity, 
while reducing norepinephrine activity  and stimulating  histamine release from the main 
cells, thereby enhancing the vasodilator effect [23]. In vivo, L-arginine reduces the level of 
NO-S-mediated superoxide [23]. It also helps to unlock eNO-S expression, which occurs 
under the action of asymmetric dimethylargrinine and L-NG-monomethyl arginine, and also 
reduces the concentration of endothelin-1, an important modulator of endothelial dysfunction 
and vasoconstrictor [13, 14, 24]. 
L-arginine-NO system, directly affects state of the endothelium, thus provides the 
functioning of the cardiovascular system [25], optimizes the function of the endothelium 
against hypercholesterolemia [26], which is important in apoptosis, balancing inflammatory 
response, and protection against oxidative damage [27]. L-arginine affects microcirculation 
and systemic circulation during infusion against background of experimental hemorrhagic 
shock, improves myocardial function, and thus contributes to the survival of animals [28]. 
Positive therapeutic effect of L-arginine correction of the endothelium in patients with 
obliteration atherosclerosis is characterized by prolonged action [13, 14, 29]. 
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Conclusions : 
1. It was found that von Willebrand factor is informative indicator of endothelial 
dysfunction in experimental rhegmatogenous retinal detachment (established differences at 
the significance level p <0.05 for the 7th day and p <0.01 for the 14th and 21st day of the 
experiment). 
2. It has been found that endothelial dysfunction is important pathogenetic link of 
rhegmatogenous retinal detachment. 
3. Three-component correction of the experimental rhegmatogenous retinal 
detachment, which consisted of cytokoline, D-asparagine and L-arginine, demonstrated its 
effectiveness in normalizing the von Willebrand factor level. 
4. It has been established that use of L-arginine, which is a nitric oxide donor, is 
effective in endothelial dysfunction correction against the background of experimental 
rhegmatogenous retinal detachment. 
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